Dual mode for enhanced precision Dual mode for enhanced precision

Dual mode for
enhanced precision

Optimized results.
Minimal side effects.

Read more
Redefining non-thermal venous therapy Redefining non-thermal venous therapy

Redefining non-thermal
venous therapy

Optimized results.
Minimal side effects

Read more

VVT Medical (TSXv:VVTM) advances vein care with minimally invasive, office-based treatments that reduce procedural complexity, recovery time, and adverse effects.

Our proprietary products deliver precise, controlled therapy for patients with varying venous pathologies.

Smart Dual-mode solutions for various vein sizes

VVT’s product portfolio includes ScleroSafeTM and V-BlockTM, two synergistic, catheter-based solutions designed to treat the widest range of vein diameters in the market.
Leveraging a proprietary mechanochemical technology that combines controlled sclerosant injection and simultaneous vessel collapse and blood aspiration, our products deliver effective vein closure with minimal side effects.

In-office, short procedure

In-office,
short procedure

Precise, controlled treatment

Precise,
controlled treatment

Streamlined results

Streamlined
results

View products

VVT in the news

"The comparable closure rates and excellent safety profile indicate that ScleroSafe may deliver near‑thermal efficacy with nonthermal simplicity"

ScleroSafe Study Published in Indian Journal of Vascular and Endovascular Surgery (2026). New clinical data from Holy Spirit Hospital and Medical Research Centre in Mumbai was published in the Indian Journal of Vascular and Endovascular Surgery, highlighting the use of ScleroSafe in patients with symptomatic varicose veins. The study demonstrated strong early vein closure rates and an excellent safety profile, reinforcing its potential as an effective non-thermal approach in modern venous care.

Read more

We attended the Expert Venous Management (EVM) 2025 Conference (May 30–31) at Englewood Hospital, New Jersey.

Led by Dr. Steve Elias with co-chairs Dr. Antonios Gasparis and Dr. Nicos Labropoulos, EVM stands out for its open, informal approach to real-world vein care. Live cases, candid discussions, and true cross-disciplinary exchange—less conference, more conversation.

VVT Medical has entered into a five-year distribution agreement with Medworks India for the commercialization of its ScleroSafe™ platform.

Under the agreement, Medworks - a leading healthcare distributor in India - will be responsible for the marketing, sales, and distribution of the ScleroSafe™ platform across the Indian market, leveraging its established network and deep expertise in advanced healthcare technologies.

We participated in the American Venous Forum (AVF) 2025 in Atlanta, one of the leading scientific meetings in venous and lymphatic disease.

The conference provided an important opportunity to engage with physicians, exchange clinical insights, and take part in discussions shaping the future of venous care, alongside vascular surgeons, interventional radiologists, and phlebologists from around the world.

TSXV Canada: Last week, we had the incredible honor of ringing the bell at the TSX Venture Exchange (TSXV), a milestone moment for VVT Medical! 

It marked the beginning of our next chapter as a publicly traded company and reinforced our commitment to advancing venous care through innovative, non-thermal, minimally invasive solutions.

Düsseldorf. Medica. We attended the Medica conference as part of the Israeli Pavilion.

We were honored to welcome Prof. Ralf Kolvenbach, esteemed vascular surgeon and distinguished member of the VVT Medical Advisory Board, to our booth. We met with numerous interested distributors, physicians, and potential partners who were fascinated by our technology.

VVT Med Inc. Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

VVT Med has expanded its European commercial presence through an exclusive distribution agreement with General Chemical Products S.A. (GCP), an established Greek medical technology company. The partnership will support the introduction and commercialization of ScleroSafe™ in Greece, further strengthening VVT Med’s European distribution network and expanding access to its minimally invasive, non-thermal technology for the treatment of venous disease.

Read more

New York, Northwell Health, Vascular & Endovascular Vein Care Center, and one of the largest healthcare systems in the U.S., has performed its first-ever ScleroSafe procedure.

“That was painless!” was the patient’s first reaction. Huge thanks to Dr. Antonios Gasparis, System Chief of Vein Disease and the entire Northwell team for their trust and professionalism.

VVT Med Expands into the Dominican Republic, Appointing Antilles Medical as Exclusive Distributor

VVT Med has expanded its commercial presence in the Americas through a distribution and evaluation agreement with Antilles Medical, appointing the company as the exclusive distributor of ScleroSafe™ in the Dominican Republic. The partnership supports the introduction of ScleroSafe™ to local physicians and represents another step in VVT Med’s strategy to expand access to its minimally invasive, non-thermal technology for the treatment of venous disease.

Read more

VVT Medical received U.S. FDA clearance for its ScleroSafe™ platform.

This milestone marks a major regulatory achievement and formally establishes the pathway for the company’s entry into the U.S. market. The clearance enables VVT Medical to begin commercial activities in the United States, supporting broader adoption of its technology by physicians and advancing the company’s global growth strategy.

ScleroSafe™ at Vein University Grand Rounds

ScleroSafe™ was featured at Vein University Grand Rounds, bringing together leading vein specialists and recognized opinion leaders in their respective fields. The session featured Dr. Lowell Kabnick, Dr. Anil Hingorani, Dr. V. Canata, Roxana Paetzold, and Dr. Tony Gasparis, who shared their perspectives on ScleroSafe™, including real-world experience, clinical outcomes, and procedural insights, as well as the growing role of non-thermal, anesthesia-free treatment options in contemporary vein care.

VVT Med Signs Largest European Distribution Agreement to Date; Distributor Joins as Investor

# VVT Med Signs Distribution Agreement in Italy VVT Med signed an exclusive distribution agreement with Uber Ros S.p.A. for the commercialization of ScleroSafe™ in Italy, Vatican City and San Marino. The agreement, the Company’s largest European distribution partnership to date, further expands ScleroSafe’s presence in the European market. As part of the partnership, Uber Ros also joined VVT Med as an investor, reflecting its confidence in the technology and its commercial potential.

Read more

VVT Medical Presented at Global Health Innovation Meets China

VVT Medical participated in Global Health Innovation Meets China, an international platform bringing together leading health-tech companies, investors, and partners from China, Europe, and the U.S. As part of the event, the Company took part in a dedicated health-tech roundtable focused on collaboration, market entry, and commercialization, presenting its non-thermal, anesthesia-free approach to venous disease and exploring opportunities for future partnerships in the Chinese and global markets.

Contact us

Contact Us

Section

Section

Consent